EMILIA

NCT00829166 📎

Regimen

Experimental
T-DM1 (trastuzumab emtansine) 3.6 mg/kg IV every 3 weeks.
Control
Lapatinib 1250 mg/day PO + capecitabine 1000 mg/m2 PO BID (days 1-14, q3w).

Population

HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.

Key finding

EMILIA established T-DM1 as 2L standard in HER2+ MBC, ending the reign of lapatinib + capecitabine. FDA approved 2013; held 2L standard until displaced by DESTINY-Breast03 in 2022. Still relevant where T-DXd is not available.

Source: PMID 23020162

Timeline

  • Publication: 2012 Nov 8

Guideline citations

  • NCCN BREAST